Imeglimin preserves islet β‐cell mass in Type 2 diabetic ZDF rats. Issue 2 (7th November 2020)

• Record Type: Journal Article
• Authors: Hallakou‐Bozec, Sophie; Kergoat, Micheline; Moller, David E.; Bolze, Sébastien
• Is Part Of: Endocrinology, diabetes & metabolism. Volume 4:Issue 2(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-11-07
• Subjects: animal models -- islet -- imeglimin -- new therapies; Endocrinology -- Periodicals; Diabetes -- Periodicals; Metabolism -- Periodicals; 616.4
• DOI: 10.1002/edm2.193
• Languages: English
• ISSNs: 2398-9238

Abstract

Abstract: Objectives: Type 2 diabetes (T2D) is driven by progressive dysfunction and loss of pancreatic β‐cell mass. Imeglimin is a first‐in‐class novel drug candidate that improves glycaemia and glucose‐stimulated insulin secretion in preclinical models and patients. Given evidence that imeglimin can attenuate β‐cell dysfunction and protect β cells in vitro, we postulated that imeglimin could also exert longer term effects to prevent pancreatic β‐cell death and preserve functional β‐cell mass in vivo . Methods: Zucker diabetic fatty (ZDF) male rats were treated by oral gavage with imeglimin at a standard dose of 150 mg/kg or vehicle, twice daily for five weeks. At treatment completion, oral glucose tolerance tests were performed in fasted animals before a thorough histomorphometry and immunohistochemical analysis was conducted on pancreas tissue slices to assess cellular composition and disease status. Results: Imeglimin treatment significantly improved glucose‐stimulated insulin secretion (augmentation of the insulinogenic index) and improved glycaemia. Both basal insulinaemia and pancreatic insulin content were also increased by imeglimin. In ZDF control rats, islet structure was disordered with few β‐cells; after imeglimin treatment, islets appeared healthier with more normal morphology in association with a significant increase in insulin‐positive β‐cells. The increase in β‐cell mass was associated with a greater degree of β‐cell proliferation in the presence of reduced apoptosis. Unexpectedly, a decrease in as a α‐cell mass was also documented due to an apparent antiproliferative effect of imeglimin on this cell type. Conclusion: In male ZDF rats, chronic imeglimin treatment corrects a paramount component of type 2 diabetes progression: progressive loss of functional β‐cell mass. In addition, imeglimin may also moderate a‐cell turnover to further ameliorate hyperglycaemia. Cumulatively, these cellular effects suggest that imeglimin may provide for disease modifying effects to preserve functional β‐cell mass. Abstract : Imeglimin is a novel drug candidate for type 2 diabetes, which has completed Phase III trials; its mechanism involves effects to augment islet β‐cell function. Imeglimin treatment of ZDF rats is shown to ameliorate glucose intolerance and increase insulinemia. Islet β‐cell mass is increased after chronic imeglimin treatment; β‐cell apoptosis is reduced, and proliferation is increased in response to imeglimin treatment.